Novel multi-modal endpoints uncovered by radiogenomics integrating CT or MRI data

Abstract

Radiologic measurements of anti-tumor response in solid tumors is a central elements needed to demonstrate treatment efficacy. However, the current use of RECIST criteria, which is the most commonly applied guideline in non-CNS clinical trials, has inherent limitations. As a result, many therapies including molecular targeted treatments and immunotherapies have shown substantial survival benefits without significant tumor shrinkage based on RECIST criteria. Thus, there is a critical unmet need to develop, test and validate alternative radiologic based criteria that do not solely rely upon tumor size shrinkage for response. This presentation will highlight some of the more promising radiologic approaches for measuring anti-tumor activity in the age of molecular targeted agents and immunotherapies. These novel imaging assessments apply feature extraction analysis based upon tumor metabolic behavior, necrosis, volumetric change, textural and Radiogenomic linkages that may not only provide a better measurement for treatment response but may also deliver predictive and prognostic information that can help improve patient selection and clinical trial design.